Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Cure Diabetes by Injection of Micro Pancreas Cell Therapy

Project description

Novel micro-organ to restore natural insulin production and regulate blood glucose levels

Lifelong insulin administration is the only therapeutic approach for diabetes patients to prevent the disease's significant and often life-threatening complications. However, the need for daily injections, the constant blood glucose monitoring and dietary constraints constitute a great nuisance in the everyday life of patients. The EU-funded Micro Pancreas project is developing a revolutionary regenerative micro-organ which can be implanted under the skin to restore natural insulin production and regulate blood glucose levels. The micro-pancreas consists of a 3D scaffold built from human pancreatic islets, thereby minimising immune responses in patients and improving islet viability and function.

Objective

Diabetes is a constantly growing concern in Europe and worldwide. Patients with Diabetes suffer from lack of insulin production. Without it, glucose remains in the blood and causes significant complications that can be both short term -seizures and fainting that could result in coma or even death, and long-term - stroke, heart disease, blindness, kidney failure and limb amputation. Betalin is developing a biologic cure to Diabetes: the Micro Pancreas that after implantation under the skin (by injection) restores natural insulin production and blood glucose regulation. Micro Pancreas is a revolutionary regenerative micro-organ, based on cell therapy comprising a proprietary organ derived 3D scaffold – Micro-Organ Matrix (MOM), isolated human pancreatic islets from donors and MSCs, which reduce the risk of immune response in patients and improve the islet viability and function. Micro Pancreas eliminates insulin dependency in diabetes patients, removing the need for daily injections and injections correlated with meals, constant blood glucose monitoring and dietary constraints.
Instead, patients get a biological implant by injection of Micro Pancreas, that generates insulin naturally in response to glucose, improving considerably daily life of patients with diabetes, including children with Type 1 Diabetes and moreover, preventing the long-term complications caused by the disease.
Following successful feasibility studies conducted thanks to the European Commission (EC) through SME Instrument Phase 1, a growing market was identified for Micro Pancreas, due to the increasing prevalence of diabetes worldwide. Total market value is expected to more than double from $6.6B in 2013, reaching a value of ~$13.6B by 2023 in drug and treatment sales, with a CAGR of 7.6%. Betalin's project will help ease the economic burden of diabetes in National Health Services while positioning itself as a leading company in the treatment of Diabetes worldwide.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

BETALIN THERAPEUTICS LTD
Net EU contribution
€ 2 288 125,00
Address
3 MENACHEM BEGIN
5268101 Ramat Gam
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 503 750,00

Participants (1)